Get started
Merck & Company, Inc.Merck & Company, Inc.Merck & Company, Inc.

Merck & Company, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

MRK trade ideas

Merck Wave Analysis – 8 April 2025- Merck broke strong support level 81.30 - Likely to fall to support level 75.00 Merck is under bearish pressure after breaking the strong support level 81.30 (the former monthly low from February, which stopped the earlier impulse wave 1). The breakout of the support level 81.30 should accelerate the active downward impulse wave v, which belongs to wave 2 of the higher order impulse wave (3) from December. Given the overriding daily downtrend, Merck can be expected to fall to the next support level 75.00, the target price for the completion of the active impulse wave v, coinciding with the daily down channel from December.
NYSE:MRKShort
by FxProGlobal
Merck & Co. (NYSE: $MRK) Sets Up Q125 Earnings Call for April 24Merck & Co. (NYSE: NYSE:MRK ) will hold its Q1 2025 earnings call on April 24 at 9:00 a.m. ET. Company executives will present financial results and performance updates during the call. As of April 4th, 2025, MRK closed at $81.47, down $4.92 (5.70%). The stock has declined steadily since peaking at $134 in June 2024. In Q4 2024, Merck posted global sales of $15.6 billion, a 7% increase from the previous year. Sales growth stood at 9% when excluding foreign exchange effects. Full-year 2024 revenue reached $64.2 billion, a 7% increase over 2023. Human health sales grew 8%, driven mainly by oncology treatments. KEYTRUDA remained the company’s top product with sales of $7.8 billion in Q4, rising 21%. WINREVAIR generated $200 million in sales, while new vaccine CAPVAXIVE added $50 million. The Animal Health division showed strong momentum, growing 13% year-over-year. Merck’s global reach extended to nearly 500 million people in 2024. However, GARDASIL vaccine sales dropped 18% in Q4 due to lower demand in China. This led Merck to pause GARDASIL shipments to the region temporarily. Operating expenses for the quarter totaled $7.4 billion. The company reported a gross margin of 80.8%, up by 3.6 percentage points. Earnings per share came in at $1.72. For 2025, Merck expects revenue between $64.1 billion and $65.6 billion. EPS guidance is set at $8.88 to $9.03, excluding foreign exchange impact. The Medicare Part D redesign could reduce revenue by about $400 million in 2025. This would affect WINREVAIR and other small molecule oncology drugs. Technical Analysis MRK stock is currently testing a major support level at $81.A confirmed breakdown at this critical level could push the stock lower. Price momentum and volume suggest a likely continuation of the bearish trend unless support holds. With the bearish pressure in place, the next support level lies at $70. The weekly chart shows consistent lower highs and lower lows since June 2024. MRK has fallen nearly 65% from its peak of $134. If the $81 current support holds, a short-term rebound is possible, with an immediate resistance target around $95. Reclaiming this level may signal early signs of a trend reversal. If a strong break at the $81 level is witnessed, the next target remains the $70 support. The current trend favors sellers. One thing to watch closely is the April 24th, 2025, earnings call as performance updates may provide clarity on near-term price direction.
NYSE:MRKShort
by DEXWireNews
How and When to switch from Selling Short to Buying Long Often times when the market is in a panic selling mode or trending down in a correction, stocks fall below their fundamental values. When that happens traders need to quickly close their sell short positions with buy to cover orders and prepare to start swing trading the velocity or momentum runs that will move price up quickly over a 3-6 day average run up to net profits as the stock rebounds back into or near its previous fundamental Level. Being able to shift from selling short to buying long takes practice and experience. It also requires more Spatial Pattern recognition Skills to enable traders to react quickly and switch trading direction. Using center line oscillators helps with this trading activity.
NYSE:MRKLong
by MarthaStokesCMT-TechniTrader
1
MRK 5M Long Investment Aggressive CounterTrend TradeAggressive CounterTrend Trade - short impulse + exhaustion volume + volumed T1 + volumed 2Sp- + weak test + first bullish bar closed entry Calculated affordable stop limit 1/2 1M take profit Hourly CounterTrend "- short impulse + 1D SOS level" Daily Trend "+ long impulse + SOS level - before 1/2 correction" Monthly CounterTrend "- short impulse + 1/2 correction + exhaustion volume?" Yearly Trend "+ long impulse + 1/2 correction + exhaustion volume?"
NYSE:MRKLong
by MishaSuvorov
Bounce Off the Bottom for Merck. MRKWe believe a downward impulse (Elliott) is finished and this is somewhat evident by the two candlestick price action. A change in the tone and flavor of candle sticks in momental OBOS area, overstretched VZO/StochRSI combo can be suggestive of a pivot and we believe this to be happening here. If the outlook is wrong then the obvious and tight stop will prevent large losses. Interstingly Ehlers StochRSI already produced a signal and momentum RSX "tipped."
NYSE:MRKLong
by Rykin_Capital
MRK Rebound in sight MRK, along with many othe rpharma stocks has taken some serious beating. But we like fear - as an opportunity- and it’s here( I dare say it) based on the bottom most will rejection, aka a shooting star. So here are my forecasts in my crystal ball:: 1. Overall Trend and Structure • Longer-Term Trend: MRK peaked near the $115–$120 region in late 2022/early 2023 and has since been making lower highs and lower lows on the weekly timeframe. This suggests a downward bias over the past 12+ months. • Recent Price Action: Price is hovering around the mid-$80s, testing support in the $80–$83 zone. This area held as support a few times in 2021–2022 and is now being revisited. • Break of Structure (BOS) & Change of Character (CHoCH) Markers: • The chart indicators label potential break-of-structure levels where bulls and bears exchanged control. • Since late 2022, these BOS levels have mostly favored the bears, confirming the downtrend. • A bullish CHoCH would require a strong close and sustained trading above the most recent swing high (somewhere in the $90–$92 zone on the weekly). 2. Key Technical Indicators 1. Stochastic Oscillator (Lower Panel) • Appears oversold or near the lower region. On a weekly timeframe, this sometimes suggests that bearish momentum could be losing steam. A bullish crossover from oversold levels often points to a short-term rebound. 2. Momentum Oscillators (e.g., RSI/MACD, if present) • While not explicitly shown, the lower indicator panel with wave-like patterns suggests momentum has been negative but may be stabilising. 3. Support & Resistance Levels • Immediate Support: $80–$83 zone. A weekly close below $80 could open the door to the mid-$70s or even $70. • Initial Resistance: $90–$92 (recent swing highs). Price needs to reclaim this region to confirm a potential bullish reversal on the weekly timeframe. • Secondary Resistance: $95–$100. If the price clears $92, this would be the next zone of overhead supply from prior consolidation. 3. Possible Scenarios & Probability Estimates Below are hypothetical scenarios with rough probability estimates, assuming no major market-wide shocks and stable macro conditions. Bullish Reversal Scenario (Est. 55–60% probability) 1. Hold Support around $80–$83: • If MRK holds above this region on a weekly closing basis, buyers may attempt a short-term bounce. • Timeframe: Could take 2–5 weeks for a solid weekly close confirming support. 2. Upside Targets: • First Target: $90–$92 (key swing high + psychological level). • Second Target: $95–$100 if price breaks and holds above $92 on strong volume. 3. Catalysts to Watch: • A weekly close above $92 would be a “change of character” from lower highs to a potential new uptrend on the weekly. • Bullish crossover in the Stochastics or MACD on the weekly. Continued Downtrend Scenario (Est. 40–45% probability) 1. Failure at $80 Support: • If the stock breaks below $80 on a weekly close, the downtrend likely continues. • Timeframe: A decisive break can happen within 1–3 weeks if sellers remain strong. 2. Downside Targets: • First Target: $75 region, near previous support levels. • Second Target: $70 if selling pressure accelerates and overall market sentiment remains weak. 3. Catalysts to Watch : • Weak earnings, lowered guidance, or broader market declines. • Stochastics remaining in oversold territory without crossing back up, indicating persistent downward momentum. 4. Trade Direction & Time Estimates • Short-Term (1–4 weeks): • Expect choppy price action around $80–$83. A near-term bounce is possible if momentum indicators turn bullish. • If a bounce materialises, watch $90–$92 as a critical resistance. • Medium-Term (2–3 months): • If bulls successfully defend $80 and break $92, a run to $95–$100 could happen by mid-spring to early summer. • Conversely, if $80 fails, the downtrend may persist into the $70s in a similar timeframe. 5. Risk Management Considerations 1. Confirm Volume & Momentum: • Wait for a weekly close above (or below) key levels ($80 support or $92 resistance) to confirm the trend direction. 2. Position Sizing: • If going long near $80 support, consider a stop-loss just below $80 (e.g., $78–$79) to limit risk. • If anticipating a breakdown, watch for confirmation (weekly close below $80) before entering short positions. 3. News & Fundamentals: • MRK is a large pharmaceutical company sensitive to drug approvals, patent news, and broader healthcare developments. Technicals alone might not capture sudden catalyst-driven moves. Final Thoughts • Most Likely Near-Term Path: A technical rebound attempt from $80–$83, but the stock must decisively clear $90–$92 to signal a genuine bullish reversal on the weekly chart. • Overall Bias: The multi-month trend is still down, so the burden of proof is on bulls to show a structural change in character. Again, these are probabilistic views. Good luck out there
NYSE:MRKLong
by OG_Doge
MerkOk this looks oversold. In fact, Oversold on multiple timeframe So here’s a technical analysis with potential price targets and trade direction: Current Market Conditions & Observations 1. Trend Direction: Bearish • The stock is in a clear downtrend, breaking multiple levels of support. • Break of Structure (BOS) labels indicate lower lows forming consistently. • A recent breakdown below support at ~$94.23 suggests further downside pressure. 2. Support & Resistance Zones: • Current support: ~$85.50 (testing support level) • Next major support: ~$80.00 (potential downside target) • Major resistance: $94.00 (previous support turned resistance) • Further resistance zones: $100 - $105 (if a reversal happens) 3. Indicators: • Stochastic RSI: Oversold territory (possible short-term relief bounce) • Volume: Elevated selling pressure, confirming the downward move. • Liquidity zones & Order Blocks: Price has entered a demand zone near $85. Trade Outlook & Price Targets • Short-Term Bearish Bias: The breakdown suggests continued downward momentum. If $85.50 breaks, next downside target is $80.00. • Possible Relief Rally: A short-term bounce could occur if buyers defend $85.50, but upside is capped at $94.00 unless strong momentum builds. • Long-Term Reversal: Would require a break back above $100-$105 to shift into a bullish structure. Trade Strategy Ideas 1. Bearish Scenario (Short Trade) • Entry: Rejection near $90-$94 zone. • Target 1: $85.50 (current support). • Target 2: $80.00 (major demand zone). • Stop-loss: Above $96.00 (invalidate bearish setup). 2. Bullish Scenario (Reversal Play) • Entry: If price holds $85.50 with strong volume. • Target 1: $94.00 (resistance). • Target 2: $100 (trend change confirmation). • Stop-loss: Below $83.00 (breaks structure). Final Outlook • Bias: Bearish unless $85.50 holds. • Short-term: Expect further downside pressure. • Medium-term: A break below $85.50 could lead to $80.00. • Long-term: Needs a reclaim above $100 to flip bullish.
NYSE:MRKLong
by OG_Doge
Trade Plan: Long Opportunity in Q2-Q3 2025Optimal Entry Zone $90-$95: A strategic accumulation zone for long-term positions. Monitor for reversal patterns (double bottom, bullish engulfing candlesticks). Targets $110: First resistance zone (aligned with the 200-day SMA and Ichimoku Base Line). $124.65: Analyst average price target and major resistance. Represents a potential 27% upside from the current price. $140+: Long-term stretch target if bullish fundamentals align. Stop Loss Below $84, as a breakdown of this level could indicate extended bearish momentum. Patience is critical for this setup. Allow the stock to establish a firm bottom around $90-$95 and wait for confirmation of reversal via technical indicators or bullish news catalysts. If the sector strengthens or macroeconomic conditions favor defensive stocks, Merck could provide a solid long-term opportunity in 2025.
NYSE:MRKLong
by AxiomEx
1
Merck & Co Inc - USD (Extended Hours) | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # Merck & Co Inc - USD (Extended Hours) - Double Formation * 121.00 USD | Area Of value | Subdivision 1 * A+ Set Up)) | Completed Survey & Entry Bias | Subdivision 2 - Triple Formation * Not Numbered Retracment | Downtrend Continuation * ((Triangle Structure)) | Subdivision 3 * Daily Time Frame | Trend Settings Condition Active Sessions On Relevant Range & Elemented Probabilities; European Session(Upwards) - US-Session(Downwards) - Asian Session(Ranging) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Sell
CAPITALCOM:MRKShort
by TradePolitics
Prescribing ProfitsMerck & Co. (MRK) is exhibiting strong bullish momentum, with a gap forming around the $95.00 level. A breakout above the $106.07 daily resistance would confirm continued strength, positioning the stock to target $120.30. This setup offers an excellent risk-to-reward ratio, with a stop-loss set at $92.74 to manage downside risk. As a leader in the pharmaceutical industry, Merck is poised for growth driven by its innovative pipeline, strong demand for its key products like Keytruda, and strategic advancements in oncology and vaccines. With consistent revenue growth and a global footprint, MRK remains a cornerstone in the healthcare sector. For a deeper dive into this setup, check out my YouTube breakdown, where I analyze the technical setup and discuss the fundamentals supporting this trade. With a combination of technical momentum and robust market fundamentals, MRK presents a compelling opportunity for traders and investors aiming for $120.30. NYSE:MRK
NYSE:MRKLong
by The_Trading_Mechanic
Merck Could Be SicklyMerck has struggled for most of the year, and now some traders may look for another push to the downside. The first pattern on today’s chart is the series of higher lows from mid-November through early last week. MRK has dropped below that line, which may be viewed as a bear-flag breakdown. Second, prices tested the 50-day simple moving average and stayed below it. That may suggest its intermediate-term trend is headed lower. Next, compare this price action with similar patterns in September. Also note that Wilder’s Relative Strength Index (RSI) slipped below its 14-day average both times. (See white arrows.) Finally, MRK is pushing against the $99.14 level where it bottomed in 2023. Are double digits the new normal for the pharmaceutical giant? TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:MRK
by TradeStation